578 related articles for article (PubMed ID: 28500170)
21. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Hobbs GS; Rozelle S; Mullally A
Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
[TBL] [Abstract][Full Text] [Related]
22. Myelofibrosis: an update on drug therapy in 2016.
Bose P; Verstovsek S
Expert Opin Pharmacother; 2016 Dec; 17(18):2375-2389. PubMed ID: 27774820
[TBL] [Abstract][Full Text] [Related]
23. New Concepts of Treatment for Patients with Myelofibrosis.
Bose P; Alfayez M; Verstovsek S
Curr Treat Options Oncol; 2019 Jan; 20(1):5. PubMed ID: 30675650
[TBL] [Abstract][Full Text] [Related]
24. Ruxolitinib.
Ajayi S; Becker H; Reinhardt H; Engelhardt M; Zeiser R; von Bubnoff N; Wäsch R
Recent Results Cancer Res; 2018; 212():119-132. PubMed ID: 30069628
[TBL] [Abstract][Full Text] [Related]
25. Current Concepts of Pathogenesis and Treatment of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Zeeh FC; Meyer SC
Hamostaseologie; 2021 Jun; 41(3):197-205. PubMed ID: 34192778
[TBL] [Abstract][Full Text] [Related]
26. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.
Vannucchi AM; Verstovsek S; Guglielmelli P; Griesshammer M; Burn TC; Naim A; Paranagama D; Marker M; Gadbaw B; Kiladjian JJ
Ann Hematol; 2017 Jul; 96(7):1113-1120. PubMed ID: 28456851
[TBL] [Abstract][Full Text] [Related]
27. Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan.
Chen YY; Huang CE; Lee KD; Chen CC
Hematology; 2016 Jan; 21(1):3-9. PubMed ID: 26214121
[TBL] [Abstract][Full Text] [Related]
28. Myeloproliferative neoplasms 2012: the John M. Bennett 80th birthday anniversary lecture.
Tefferi A
Leuk Res; 2012 Dec; 36(12):1481-9. PubMed ID: 22917768
[TBL] [Abstract][Full Text] [Related]
29. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
[TBL] [Abstract][Full Text] [Related]
30. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
31. JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease.
Evrot E; Ebel N; Romanet V; Roelli C; Andraos R; Qian Z; Dölemeyer A; Dammassa E; Sterker D; Cozens R; Hofmann F; Murakami M; Baffert F; Radimerski T
Clin Cancer Res; 2013 Nov; 19(22):6230-41. PubMed ID: 24081976
[TBL] [Abstract][Full Text] [Related]
32. JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation?
Santos FP; Verstovsek S
Anticancer Agents Med Chem; 2012 Nov; 12(9):1098-109. PubMed ID: 22583424
[TBL] [Abstract][Full Text] [Related]
33. Pacritinib: a new agent for the management of myelofibrosis?
Beauverd Y; McLornan DP; Harrison CN
Expert Opin Pharmacother; 2015; 16(15):2381-90. PubMed ID: 26389774
[TBL] [Abstract][Full Text] [Related]
34. Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation.
Hexner E; Roboz G; Hoffman R; Luger S; Mascarenhas J; Carroll M; Clementi R; Bensen-Kennedy D; Moliterno A
Br J Haematol; 2014 Jan; 164(1):83-93. PubMed ID: 24903629
[TBL] [Abstract][Full Text] [Related]
35. Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors.
Randhawa J; Ostojic A; Vrhovac R; Atallah E; Verstovsek S
J Hematol Oncol; 2012 Aug; 5():43. PubMed ID: 22852872
[TBL] [Abstract][Full Text] [Related]
36. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis.
Mesa RA
IDrugs; 2010 Jun; 13(6):394-403. PubMed ID: 20506062
[TBL] [Abstract][Full Text] [Related]
37. How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera.
Reiter A; Harrison C
Curr Hematol Malig Rep; 2016 Oct; 11(5):356-67. PubMed ID: 26894383
[TBL] [Abstract][Full Text] [Related]
38. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2023 May; 98(5):801-821. PubMed ID: 36680511
[TBL] [Abstract][Full Text] [Related]
39. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.
Verstovsek S; Passamonti F; Rambaldi A; Barosi G; Rosen PJ; Rumi E; Gattoni E; Pieri L; Guglielmelli P; Elena C; He S; Contel N; Mookerjee B; Sandor V; Cazzola M; Kantarjian HM; Barbui T; Vannucchi AM
Cancer; 2014 Feb; 120(4):513-20. PubMed ID: 24258498
[TBL] [Abstract][Full Text] [Related]
40. Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor?
Lancman G; Mascarenhas J
Expert Rev Hematol; 2017 Jan; 10(1):23-28. PubMed ID: 27882812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]